甲状腺癌诊断市场－全球产业规模、份额、趋势、机会、预测：按类型、技术、最终用途、地区和竞争格局划分，2021-2031年

全球甲状腺癌诊断市场预计将从 2025 年的 27.3 亿美元成长到 2031 年的 35.2 亿美元，复合年增长率为 4.33%。

该领域涵盖多种临床评估方法，旨在识别和表征甲状腺恶性肿瘤，包括高解析度成像、细针穿刺切片检查和分子基因组学检测。推动该市场成长要素是全球内分泌疾病盛行率的不断上升，以及为改善治疗效果而对早期疾病检测的迫切需求。日益加重的疾病负担需要严格的筛检通讯协定，并直接推动了专业诊断技术的应用。根据美国癌症协会 (ACS) 的数据，到 2025 年，美国预计将新增约 44,020 例甲状腺癌病例，这凸显了迫切需要精准的诊断设备来有效应对如此庞大的患者群体。

儘管市场呈现成长态势，但仍面临一项重大挑战：低度甲状腺结节的过度诊断，这种做法往往导致不必要的手术和过度治疗。为此，监管机构修订了筛检指南，建议对小型、低风险结节采取更保守的治疗方案。这些临床实践的改变造成了报销的不确定性，并减少了轻症病例的诊断程序，阻碍了市场的进一步扩张。

市场驱动因素

全球甲状腺癌发生率的上升是诊断市场的主要驱动力，因此需要製定完善的筛检通讯协定来应对不断增长的患者数量。这种成长在年轻人群体中尤为显着，迫使医疗系统加强诊断能力，以便早期疗育。世界卫生组织（WHO）国际癌症研究机构（IARC）于2025年11月发布的题为《青少年和青年甲状腺癌》的研究报告显示，2022年全球该年龄层新增甲状腺癌病例超过23.7万例。这一成长趋势也体现在各国统计数据中；例如，英国癌症研究中心在2025年9月报告称，该地区每年约有4000例新增甲状腺癌病例，这凸显了在不同人群中持续开发有效检测方法的必要性。

同时，分子诊断和基因组分析的整合正在改变临床工作流程。这有助于解决难以确定性质的甲状腺结节的诊治难题。先进的基因组分类工具使医生能够更准确地区分良性和恶性结节，从而减少不必要的诊断性手术，并确保资源的有效利用。精准医疗的转型体现在专业检测产品的显着成长。 Verasite在2025年2月发布的2024年第四季及全年财报中宣布，其Affima基因组检测的销量增长了12%，2024年全年检测量超过6万次。如此高的普及率表明，分子检测正迅速成为标准诊疗流程，并透过高附加价值诊断程序推动市场收入成长。

市场挑战

甲状腺癌诊断市场面临的一大障碍是临床诊疗模式的转变，即减少对低度甲状腺结节的过度诊断。过去，发现小型、低风险结节通常会促使医生进行积极的诊断评估，但目前的临床实践越来越倾向于对小型病灶采取积极后续观察而非即时进行细针穿刺切片检查或分子检测。这种保守治疗的转变直接降低了诊断干预的频率，减少了检测总数，并限制了诊断机构的收入来源。

由于医疗系统实施更严格的报销标准以消除低风险病例相关的不必要成本，检测数量的下降给市场带来了挑战。根据加拿大癌症协会估计，到2025年，加拿大预计将有约6900人被诊断出患有甲状腺癌。虽然这种发病率扩大了潜在患者群体，但临床指南选择性的提高意味着接受全面诊断的甲状腺结节患者数量将会减少。因此，由于医疗机构将这些高精度诊断工具的使用限制在高风险恶性肿瘤，而非用于对轻微结节进行常规筛检，企业面临着获取这些工具管道受限的困境。

市场趋势

将人工智慧 (AI) 和机器学习技术应用于诊断影像，从根本上改变了甲状腺癌的检测方式，提高了超音波检查的准确性，并优化了临床操作。人工智慧演算法越来越多地被用于评估超音波观察，与传统的视觉分析相比，它能更准确地区分良性和恶性结节。这项技术进步正在消除不同检查者之间的操作差异，并显着提高临床效率。例如，在 RamSoft 于 2025 年 9 月发布的新闻稿「RamSoft 与 Koios Medical 合作」中，他们指出，将 Koios DS 人工智慧软体整合到其放射科平台后，诊所可以将影像解读时间缩短 49%，提高病患接诊能力，并在不影响诊断准确性的前提下，更有效地应对不断增长的病患数量。

同时，标靶治疗伴随诊断的兴起正推动着快速次世代定序(NGS) 在进行性甲状腺恶性肿瘤诊断中的应用。随着针对 RET 和 BRAF 等特定突变的新疗法逐渐成为标准治疗方案，迫切需要快速、全面的基因组分析，以便在确诊后立即确定治疗方案。这一趋势正超越简单的结节分类，将重点转向检测进行性癌症中可治疗的突变，从而优化治疗策略。 2025 年 8 月《CAP TODAY》杂誌发表了一篇题为「FDA核准的新型快速 NGS 解决方案上市」的报告，重点介绍了新核准的Oncomine Dx Express 检测可在短短 24 小时内提供组织检体的伴随诊断结果。这种快速结果交付将使高风险甲状腺癌患者能够及时获得个人化治疗方案，从而加强医疗保健领域的协调。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球甲状腺癌诊断市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依类型（乳头状癌、滤泡状癌、其他）
  • 透过检查方法（血液检查、影像诊断、切片检查、其他）
  • 透过申请（医院检查室、癌症诊断中心、研究所等）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美甲状腺癌诊断市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲甲状腺癌诊断市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区甲状腺癌诊断市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲甲状腺癌诊断市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲甲状腺癌诊断市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球甲状腺癌诊断市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• F Hoffmann-La Roche AG
• Abbott Laboratories Inc
• Thermo Fisher Scientific Inc
• General Electric Co
• Siemens Healthcare GmbH
• Bio-Rad Laboratories Inc
• Toshiba Corporation
• Koninklijke Philips NV
• Agilent Technologies Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Thyroid Cancer Diagnostics Market is projected to expand from a valuation of USD 2.73 Billion in 2025 to USD 3.52 Billion by 2031, registering a compound annual growth rate of 4.33%. This sector encompasses a diverse range of clinical evaluations, such as high-resolution imaging, fine needle aspiration biopsy, and molecular genomic testing, all designed to identify and characterize thyroid malignancies. The market is primarily driven by the increasing global prevalence of endocrine disorders and a strong push for early disease detection to enhance therapeutic results. This rising disease burden requires rigorous screening protocols, which directly stimulates the adoption of specialized diagnostic technologies. Data from the American Cancer Society indicates that approximately 44,020 new cases of thyroid cancer were diagnosed in the United States in 2025, highlighting the urgent need for precise diagnostic instruments to effectively handle the substantial patient volume.

Despite this growth trajectory, the market faces a significant obstacle concerning the overdiagnosis of indolent thyroid nodules, a practice that frequently results in unnecessary surgeries and overtreatment. In response, regulatory authorities have revised screening guidelines to recommend more conservative management for small, low-risk nodules. These changes in clinical practice create uncertainty regarding reimbursement and decrease the number of diagnostic procedures conducted for minor cases, which subsequently hinders broader market expansion.

Market Driver

The escalating global incidence of thyroid cancer serves as a major driver for the diagnostics market, creating a necessity for robust screening protocols to accommodate increasing patient numbers. This surge is especially noticeable among younger populations, forcing healthcare systems to enhance their diagnostic capacities to facilitate earlier intervention. According to the World Health Organization's International Agency for Research on Cancer study titled 'Thyroid cancer in adolescents and young adults' from November 2025, there were over 237,000 new cases globally within this demographic in 2022. This increasing burden is also reflected in national statistics; for example, Cancer Research UK reported in September 2025 that approximately 4,000 new thyroid cancer cases are diagnosed annually in the region, emphasizing the ongoing requirement for effective detection methods across various populations.

In parallel, the rising integration of molecular diagnostics and genomic profiling is revolutionizing clinical workflows by resolving the difficulty of managing indeterminate thyroid nodules. Advanced genomic classifiers enable physicians to differentiate between benign and malignant nodules with improved precision, thereby lowering the rate of unnecessary diagnostic surgeries and ensuring better resource utilization. This movement toward precision medicine is demonstrated by the significant adoption of specialized testing products. In its 'Fourth Quarter and Full Year 2024 Financial Results' released in February 2025, Veracyte announced that its Afirma genomic test volume increased by 12% to exceed 60,000 tests for the full year 2024. Such strong adoption figures suggest that molecular testing is quickly becoming a standard of care, boosting market revenue through the use of higher-value diagnostic procedures.

Market Challenge

The principal obstacle restricting the thyroid cancer diagnostics market is the clinical shift aimed at mitigating the overdiagnosis of indolent thyroid nodules. Although the detection of minute, low-risk nodules historically triggered aggressive diagnostic evaluations, current practice standards increasingly prioritize active surveillance instead of immediate fine needle aspiration biopsy or molecular testing for small lesions. This move toward conservative management directly lowers the frequency of diagnostic interventions, thereby reducing the total volume of tests conducted and constraining revenue streams for diagnostic providers.

This decline in procedural volume creates a challenging landscape for market growth, as healthcare systems implement stricter reimbursement criteria to eliminate unnecessary expenses related to low-risk cases. According to estimates from the Canadian Cancer Society, approximately 6,900 individuals in Canada will be diagnosed with thyroid cancer in 2025. Although this incidence rate adds to the potential patient pool, the growing selectivity in clinical guidelines implies that a smaller proportion of patients with thyroid nodules will receive comprehensive diagnostic profiling. As a result, companies encounter limited utilization of premium diagnostic tools, since providers are restricting these advanced modalities to high-risk malignancies rather than using them for the routine screening of minor nodules.

Market Trends

The incorporation of Artificial Intelligence and Machine Learning into imaging is fundamentally transforming thyroid cancer detection by improving ultrasound accuracy and optimizing clinical operations. AI algorithms are increasingly being utilized to assess sonographic characteristics, assisting clinicians in distinguishing between benign and malignant nodules with greater precision than traditional visual analysis provides. This technological progress addresses the inconsistency in operator performance and notably boosts practice efficiency. For instance, RamSoft's September 2025 press release, 'RamSoft Partners with Koios Medical,' noted that integrating Koios DS AI software into radiology platforms allows clinics to reduce interpretation time by 49% while enhancing patient throughput, enabling providers to handle growing patient volumes more effectively without sacrificing diagnostic confidence.

At the same time, the rise of Companion Diagnostics for Targeted Therapies is fueling the growth of rapid next-generation sequencing (NGS) applications for advanced thyroid malignancies. As new therapies that target specific mutations such as RET and BRAF become standard practice, there is an urgent requirement for rapid and extensive genomic profiling to inform treatment choices immediately following diagnosis. This trend extends beyond basic nodule classification to focus on detecting actionable alterations in aggressive cancers to refine therapeutic strategies. A report in CAP TODAY from August 2025, titled 'Introduction of a new FDA approved rapid NGS solution,' highlights that the recently approved Oncomine Dx Express Test can provide companion diagnostic results from tissue samples within just 24 hours. This faster turnaround ensures that patients with high-risk thyroid cancer receive personalized treatment plans without substantial delays, thereby enhancing overall care coordination.

Key Market Players

• F Hoffmann-La Roche AG
• Abbott Laboratories Inc
• Thermo Fisher Scientific Inc
• General Electric Co
• Siemens Healthcare GmbH
• Bio-Rad Laboratories Inc
• Toshiba Corporation
• Koninklijke Philips NV
• Agilent Technologies Inc

Report Scope

In this report, the Global Thyroid Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Thyroid Cancer Diagnostics Market, By Type

• Papillary Carcinoma
• Follicular Carcinoma
• Others

Thyroid Cancer Diagnostics Market, By Technique

• Blood Test
• Imaging
• Biopsy
• Others

Thyroid Cancer Diagnostics Market, By End-use

• Hospital Laboratories
• Cancer Diagnostic Centers
• Research Institutes
• Others

Thyroid Cancer Diagnostics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Thyroid Cancer Diagnostics Market.

Available Customizations:

Global Thyroid Cancer Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Thyroid Cancer Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Papillary Carcinoma, Follicular Carcinoma, Others)
  • 5.2.2. By Technique (Blood Test, Imaging, Biopsy, Others)
  • 5.2.3. By End-use (Hospital Laboratories, Cancer Diagnostic Centers, Research Institutes, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Thyroid Cancer Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Technique
  • 6.2.3. By End-use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Thyroid Cancer Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Technique
      • 6.3.1.2.3. By End-use
  • 6.3.2. Canada Thyroid Cancer Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Technique
      • 6.3.2.2.3. By End-use
  • 6.3.3. Mexico Thyroid Cancer Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Technique
      • 6.3.3.2.3. By End-use

7. Europe Thyroid Cancer Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Technique
  • 7.2.3. By End-use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Thyroid Cancer Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Technique
      • 7.3.1.2.3. By End-use
  • 7.3.2. France Thyroid Cancer Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Technique
      • 7.3.2.2.3. By End-use
  • 7.3.3. United Kingdom Thyroid Cancer Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Technique
      • 7.3.3.2.3. By End-use
  • 7.3.4. Italy Thyroid Cancer Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Technique
      • 7.3.4.2.3. By End-use
  • 7.3.5. Spain Thyroid Cancer Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Technique
      • 7.3.5.2.3. By End-use

8. Asia Pacific Thyroid Cancer Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Technique
  • 8.2.3. By End-use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Thyroid Cancer Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Technique
      • 8.3.1.2.3. By End-use
  • 8.3.2. India Thyroid Cancer Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Technique
      • 8.3.2.2.3. By End-use
  • 8.3.3. Japan Thyroid Cancer Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Technique
      • 8.3.3.2.3. By End-use
  • 8.3.4. South Korea Thyroid Cancer Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Technique
      • 8.3.4.2.3. By End-use
  • 8.3.5. Australia Thyroid Cancer Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Technique
      • 8.3.5.2.3. By End-use

9. Middle East & Africa Thyroid Cancer Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Technique
  • 9.2.3. By End-use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Thyroid Cancer Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Technique
      • 9.3.1.2.3. By End-use
  • 9.3.2. UAE Thyroid Cancer Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Technique
      • 9.3.2.2.3. By End-use
  • 9.3.3. South Africa Thyroid Cancer Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Technique
      • 9.3.3.2.3. By End-use

10. South America Thyroid Cancer Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Technique
  • 10.2.3. By End-use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Thyroid Cancer Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Technique
      • 10.3.1.2.3. By End-use
  • 10.3.2. Colombia Thyroid Cancer Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Technique
      • 10.3.2.2.3. By End-use
  • 10.3.3. Argentina Thyroid Cancer Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Technique
      • 10.3.3.2.3. By End-use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Thyroid Cancer Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. F Hoffmann-La Roche AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Abbott Laboratories Inc
• 15.3. Thermo Fisher Scientific Inc
• 15.4. General Electric Co
• 15.5. Siemens Healthcare GmbH
• 15.6. Bio-Rad Laboratories Inc
• 15.7. Toshiba Corporation
• 15.8. Koninklijke Philips NV
• 15.9. Agilent Technologies Inc

16. Strategic Recommendations

17. About Us & Disclaimer